KKRC
OBIO icon

Kohlberg Kravis Roberts & Co’s Orchestra BioMed OBIO Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-248,924
Closed -$2.48M – 218
2022
Q2 		$2.48M Sell
248,924
-17
-0% -$169 0.03% 87
2022
Q1 		$2.47M Buy
248,941
+79,956
+47% +$790K 0.02% 97
2021
Q4 		$1.7M Buy
+168,985
New +$1.67M 0.01% 85

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's OBIO Position: Q3 2022 in Review

Kohlberg Kravis Roberts & Co sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 248,924 shares — an estimated $2.48M sold.

Kohlberg Kravis Roberts & Co first reported a position in OBIO in Q4 2021 and held it in 3 quarters. The position peaked at $2.48M in Q2 2022. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

  • Kohlberg Kravis Roberts & Co reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
  • Kohlberg Kravis Roberts & Co sold 248,924 Orchestra BioMed shares in Q3 2022, an estimated $2.48M.
  • Kohlberg Kravis Roberts & Co first reported a position in Orchestra BioMed in Q4 2021 and held it in 3 quarters.
  • Kohlberg Kravis Roberts & Co's Orchestra BioMed position peaked at $2.48M in Q2 2022.
  • 23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q3 2022, filed 14 Nov 2022.